Cohance Lifesciences to host Q1 FY27 earnings call on Aug 5
NiveshIQ
NSE: COHANCE · Healthcare
Cohance Lifesciences Ltd.
₹431.30▲ ₹5.55 (+1.30%)
Price Chart · Daily closes
1Y
6M
3M
1M
1W
1D
⚡ Intelligence Signals
5 active
🟢 Bullish Earnings Catalyst
📊 RS Laggard (5D)
🔄 Sector Sweep
⚡ Signals Aligned
📉 Pullback
NiveshIQ has detected 5 active signals on COHANCE. Sign up free to see what each signal means and how it affects the stock.
Unlock signals — freeExpected Move
1D / 1W / 1M range derived from news, fundamentals & technicals
1 Day
±1.8%
1 Week
±4.2%
1 Month
±9.6%
Confidence Score
Based on historical directional & magnitude accuracy for this stock
74
/ 100
About Cohance Lifesciences Ltd.
Cohance Lifesciences Limited is a leading contract research, development, and manufacturing company in the healthcare sector, with a strong presence in India, the United States, Europe, and internationally. The company offers a diverse range of products, including small molecule APIs, advanced intermediates, and specialty chemicals, serving pharmaceutical, biotechnology, and chemical companies. In FY26, the company reported revenue of ₹2269 Cr and net income of ₹179 Cr. Recent developments include a significant decline in profit, with a 76% plunge in Q3 FY26 due to margin pressures. The company is expected to attend investor meets in June, providing an opportunity for stakeholders to engage with management. Despite recent challenges, the company's strong presence in the contract research a
Financial Highlights
| Metric | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | ₹1,052 Cr -21.50% | ₹2,608 Cr +147.90% | ₹2,269 Cr -13.00% |
| EBITDA Margin | 38.40% | 30.52% | 20.32% |
| Net Profit | ₹301.00 Cr -26.80% | ₹483.00 Cr +60.50% | ₹150.12 Cr -68.90% |
| EPS | ₹11.81 | ₹19.14 | ₹4.69 |
Annual figures in Indian Rupees (Crores). Source: BSE filings.
Recent News
Cohance Lifesciences Ltd is Rated Strong Sell
Cohance Lifesciences Ltd is Rated Strong Sell
🔒
+ 3 more stories about Cohance Lifesciences Ltd.
Full news feed with AI impact summaries, synced in real time.
Sign up free — it's instantStrategic Outlook
- Q4FY26 results: revenue ₹619 Cr, PAT ₹8 Cr, EPS ₹0.51, EBITDA margin 15.6%. Growth context: revenue YoY -26.3%, PAT YoY -92.9%, revenue QoQ +13.6%, PAT QoQ -71.3%. Street verdict: strong miss, revenue surprise -3.0%, PAT surprise -22.5%.
Product pipeline delivery, domestic demand, export mix, approvals, and margin discipline remain the key forward drivers ...
FY26 (last completed FY): revenue ₹2, 269 Cr, PAT ₹150 Cr, EBITDA margin 20.3%, EPS ₹4.69. Year-on-year: revenue YoY -13...
🔒
+ 3 more outlook points
Growth drivers, key risks, and upcoming catalysts — unlocked free.
Sign up free — it's instantEverything you unlock with a free account
⚡Intelligence Signals — AI-detected patterns across news, earnings & technicals
📈Price Chart — 1D to 1Y daily closes for COHANCE
🎯Expected Move — 1D / 1W / 1M range from news, fundamentals & technicals
🧠Confidence Score — Historical directional & magnitude accuracy for this stock
🎙Analyst Target Price — Consensus target with buy / hold / sell breakdown
📰Full News Feed — All stories synced in real time with AI impact summaries
🔭Strategic Outlook — Growth drivers, risks & upcoming catalysts
📊Watchlist & Portfolio — Track COHANCE alongside your other holdings
Unlock full COHANCE research — free
No credit card · No trial · Always free to start
Frequently Asked Questions
What AI signals does NiveshIQ provide for Cohance Lifesciences Ltd.?
NiveshIQ detects active intelligence signals for Cohance Lifesciences Ltd. (COHANCE) — including earnings catalysts, relative strength patterns, sector sweeps, and pullback setups. It also shows an Expected Move (1D/1W/1M range based on news, fundamentals and technicals) and a Confidence Score based on historical directional and magnitude accuracy. These are exclusive to NiveshIQ.
What are the key financials for Cohance Lifesciences Ltd.?
Cohance Lifesciences Ltd. operates in the Healthcare sector with a market capitalisation of ₹1,608,316.7L Cr. Revenue, net profit, EPS and EBITDA margins across the last three annual periods are shown above, sourced from BSE filings.
Does NiveshIQ provide investment advice?
No. NiveshIQ provides educational market intelligence and research context, not investment advice or buy/sell recommendations.